Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
4(57%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
29%
Ph not_applicable
3
43%
Ph phase_3
2
29%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
2(28.6%)
N/ANon-phased studies
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Completed(2)
Other(1)

Detailed Status

Recruiting4
Completed2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (28.6%)
Phase 32 (28.6%)
N/A3 (42.9%)

Trials by Status

completed229%
recruiting457%
unknown114%

Recent Activity

4 active trials
Showing 5 of 7
completednot_applicable

Rehabilitation After Ileo-anal Pouch Surgery

NCT03148600
recruitingnot_applicable

Preventative Intervention for Cholera for 7 Days

NCT05166850
recruitingnot_applicable

Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.

NCT02964858
recruitingphase_2

Dose Escalation Using Hypoxia-adjusted Radiotherapy

NCT06087614
recruitingphase_2

Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer

NCT04989725
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03148600Not Applicable

Rehabilitation After Ileo-anal Pouch Surgery

Completed
NCT05166850Not Applicable

Preventative Intervention for Cholera for 7 Days

Recruiting
NCT02964858Not Applicable

Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.

Recruiting
NCT06087614Phase 2

Dose Escalation Using Hypoxia-adjusted Radiotherapy

Recruiting
NCT04989725Phase 2

Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer

Recruiting
NCT01168479Phase 3

FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer

Completed
NCT04046705Phase 3

Comparison of Allogeneic Matched Related Haematopoietic Stem Cell Transplantation After a Reduced Intensity Conditioning Regimen With Standard of Care in Adolescents and Adults With Severe Sickle Cell Disease

Unknown

All 7 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
7